TLR3 and neoplasm: Huang et al. constructed a combination of TLR3 agonist Hiltonol and ICD inducer ELANE to engineer TEXs that can activate DCs in situ in a mouse xenograft model of poorly immunogenic triple-negative breast cancer and tumor organs derived from patients with hot tears; both produced effective tumor suppression [104].